Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

A Large Simple Safety Study of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

This is a multi-center study to evaluate the long-term safety of arformoterol 15 mcg twice daily (BID) in the treatment of subjects with moderate-to-severe COPD. Study participation will consist of a total of 6 visits over approximately 1 year.

Study Overview

• Status: Completed
• Conditions: Chronic Obstructive Pulmonary Disease
• Intervention / Treatment: Drug: Arformoterol; Drug: Placebo

Detailed Description

This is a multi-center, double-blind, randomized, placebo-controlled, parallel-group, outpatient, safety study to evaluate the long-term safety of arformoterol 15 mcg twice daily (BID) in the treatment of subjects with moderate-to-severe COPD. The administration of arformoterol in subjects with moderate to severe COPD will not result in a meaningfully greater incidence of respiratory death and COPD exacerbation -related hospitalizations compared to placebo (nebulized saline and non-long-acting beta2-agonist [LABA] COPD standard of care treatments). This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

• Study Type: Interventional
• Enrollment (Actual): 841
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 25233
      • Jefferson Clinic
    • Birmingham, Alabama, United States, 35235
      • Alabama Clinical Therapeutic, LLC
    • Brimingham, Alabama, United States, 35209
      • Achieve Clinical Research
    • Jasper, Alabama, United States, 35501
      • Jasper Summit Research, LLC
  • California
    • Anaheim, California, United States, 92801
      • Chest Critical Care Consultants
    • Fullerton, California, United States, 92835
      • California Research Medical Group
    • Riverside, California, United States, 92506
      • Integrated Research Group
    • Roseville, California, United States, 95661
      • Quality Control Research Inc.
    • Sacramento, California, United States, 95825
      • Sockolov and Sockolov APC
    • Sacremento, California, United States, 95823
      • Centers for Clinical Trials of Sacremento
    • San Diego, California, United States, 92120
      • Institute of HealthCare Assessment, Inc.
  • Colorado
    • Denver, Colorado, United States, 80206
      • National Jewish Health
  • Florida
    • Chiefland, Florida, United States, 32626
      • Southeast Clinical Research
    • Clearwater, Florida, United States, 33765
      • Clinical Research of West Florida, Inc.
    • Clearwater, Florida, United States, 33761
      • Tampa Bay Medical Research Inc.
    • DeLand, Florida, United States, 32720
      • Avail Clinical Research
    • Kissimmee, Florida, United States, 34741
      • The Lung Clinic, P.A.
    • Orlando, Florida, United States, 32806
      • DCT
    • Tampa, Florida, United States, 33603
      • Clinical Research of West Florida
  • Georgia
    • Canton, Georgia, United States, 30114
    • Columbus, Georgia, United States, 31904
      • Southeast Regional Research Group
    • Decatur, Georgia, United States, 30033
      • Atlanta Pharmaceutical Research
    • Marietta, Georgia, United States, 30060
      • Wellstar Marietta Pulmonary Medicine
    • Rincon, Georgia, United States, 31326
      • Southeast Regional Research Group
  • Indiana
    • Evansville, Indiana, United States, 47714
      • Medisphere Medical Research Center
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • University of Iowa Hospitals and Clinics
  • Kentucky
    • Hazard, Kentucky, United States, 41701
      • Kentucky Lung Clinic
  • Louisiana
    • Lafayette, Louisiana, United States, 70503
      • Bendel Medical Research Center, LLC
  • Michigan
    • Ann Arbor, Michigan, United States, 48106
      • ClinSite LLC
  • Minnesota
    • Minneapolis, Minnesota, United States, 55402
      • Clinical Research Institute Inc.
  • Missouri
    • St. Charles, Missouri, United States, 63301
      • Midwest Chest Consultants
    • St. Louis, Missouri, United States, 63141
      • C.A.R.E. Clinical Research
  • New Jersey
    • Berlin, New Jersey, United States, 08009
      • Comprehensive Clinical Research
    • Cherry Hill, New Jersey, United States, 08003
      • Delaware Valley Clinical Research
  • New York
    • New York, New York, United States, 10016
      • New York Pulmonary and Clinical Care Associates, PC
    • Newburgh, New York, United States, 12550
      • ENT & Allergy Associates
    • Rochester, New York, United States, 14609
      • Rochester Clinical Research
    • Rochester, New York, United States, 14618
      • AAIR Research Center
  • North Carolina
    • Charlotte, North Carolina, United States, 28207
      • American Health Research Inc.
    • Winston-Salem, North Carolina, United States, 27103
      • Piedmont Medical Research
  • Ohio
    • Akron, Ohio, United States, 44313
      • DayStar Clinical Research, Inc.
    • Cincinnati, Ohio, United States, 45231
      • Bernstein Clinical Research Center
  • Oregon
    • Medford, Oregon, United States, 97504
      • Clinical Research Institute of Southern Oregon, PC
    • Portland, Oregon, United States, 97216
      • Allergy Associates Research Center
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19142
      • Arcuri Clinical Research, LLC
  • Rhode Island
    • Pawtucket, Rhode Island, United States, 02860
      • Biomedical Research Alliance at Hypertension and Nephrology
    • Warwick, Rhode Island, United States, 02886
      • Omega Medical Research
  • South Carolina
    • Charleston, South Carolina, United States, 29406
      • Lowcountry Lung & Critical Care, PA
    • Columbia, South Carolina, United States, 29201
      • Neem Research Group, Inc.
    • Gaffney, South Carolina, United States, 29340
      • Gaffney Pharmaceutical Research
    • Greenville, South Carolina, United States, 29615
      • Greenville Pharmaceutical Research
    • Greenville, South Carolina, United States, 29615
      • Upstate Pharmaceutical Research
    • Greer, South Carolina, United States, 29651
      • Mountain View Clinical Research, Inc.
    • Spartanburg, South Carolina, United States, 29303
      • S. Carolina Pharmaceutical Research
    • Union, South Carolina, United States, 29379
      • CU Pharmaceutical Research
  • Tennessee
    • Knoxville, Tennessee, United States, 37920
      • Volunteer Research Group
    • Knoxville, Tennessee, United States, 37909
      • Allergy Associates
  • Texas
    • Arlington, Texas, United States, 76014
      • DCT
    • Houston, Texas, United States, 77030
      • Baylor College of Medicine, Clinical Studies Unit, Ben Taub General Hospital
    • Houston, Texas, United States, 77030
      • VAMC
    • Kingwood, Texas, United States, 77339
      • Kingwood Research Institute, LLC
    • San Antonio, Texas, United States, 78229
      • Diagnostics Research Group
    • San Antonio, Texas, United States, 78212
      • Physician PrimeCare Research
    • Sugar Land, Texas, United States, 77878
      • DCT
    • Webster, Texas, United States, 77598
      • Southeast Research Institute
  • Utah
    • Provo, Utah, United States, 84604
      • National Clinical Resources, Inc.
    • Salt Lake City, Utah, United States, 84107
      • Utah Clinical Trials LLC
  • Virginia
    • Charlottesville, Virginia, United States, 22911
      • Charlottesville Medical Research Inc.
    • Manassas, Virginia, United States, 20110
      • Manassas Clinical Research Center
    • Richmond, Virginia, United States, 23219
      • Dominion Medical Associates
    • Richmond, Virginia, United States, 23225
      • Pulmonary Associates of Richmond Inc.
    • Richmond, Virginia, United States, 23229
      • Pulmonary Associates of Richmond, Inc.
  • Washington
    • Tacoma, Washington, United States, 98405
      • Pulmonary Consultants, PLLC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject must give written informed consent, including privacy authorization as well as adherence to concomitant medication withholding periods, prior to participation.
• Females considered not of childbearing potential must be surgically sterile (total hysterectomy, bilateral salpingo oophorectomy, or tubal ligation) or post-menopausal, which is defined as a complete cessation of menstruation for at least 1 year.
• Male and female subjects must be at least 40 years old at the time of consent.
• Subjects must have a pre-established, documented primary clinical diagnosis of non-asthmatic COPD or are referred for diagnosis of non-asthmatic COPD.
• Subjects must have a baseline FEV1 of ≤50% predicted volume at Visits 1 and 2 (pre-dose).
• Subjects must have a FEV1 >0.50 L at either Visit 1 or 2 (pre-dose).
• Subject's respiratory status must be clinically stable.
• Subjects must have a FEV1/forced vital capacity (FVC) ratio of ≤70% at either Visit 1 or 2 (pre-dose).
• Subjects must have had at least 1 COPD exacerbation within the last year (defined as initiation or an increase in the dose of oral steroids or antibiotics for the treatment of COPD).
• Subjects must have a ≥15 pack-year smoking history and a baseline breathlessness severity grade of ≥2 (Modified Medical Research Council [MMRC] Dyspnea Scale Score) at Visit 2.
• Female subjects ≤65 years of age must have a negative serum pregnancy test conducted at Visit 1 prior to randomization. Females of childbearing potential must be using an acceptable method of birth control.
• Subjects' overall health must be sufficiently stable to complete the study requirements based on the screening physical examination (defined as the absence of any clinically relevant abnormalities), medical history, 12-lead ECG, and clinical laboratory values (hematology, serum chemistry and urinalysis), and vital signs (heart rate, respiratory rate, and blood pressure) that have been conducted within 30 days of Visit 2 (randomization). If any of the hematology, chemistry, or urinalysis results are not within the laboratory's reference range, then the subject can be included only if the investigator judges the deviations to be not clinically significant.
• Subjects must have a minimum blood pressure of 105/60 mmHg and a minimum resting pulse of 50 bpm at Screening Visit 1. Subjects who do not meet these criteria at Screening Visit 1 must meet the criteria on the first day of dosing (Day 1) in order to be eligible for the study. Subjects with a medical condition which causes low blood pressure or low heart rate, but, in the opinion of the Principal Investigator or designee the medical condition could resolve, may be rescreened when the condition is resolved.
• Subjects must be willing and able to complete all study questionnaires and logs reliably.
• Subjects must be willing and able to comply with study procedures and visit schedule.
• Subjects must have sufficient understanding of English to complete all questionnaires and logs.

Exclusion Criteria:

• Female subjects who are pregnant or lactating.
• Subjects with a history of asthma, with the exception of asthma diagnosed in childhood.
• Subjects with a blood eosinophil count >5% of total white blood cell count.
• Subjects with a febrile illness within 3 days before Screening.
• Subjects with a malignant neoplasm other than non melanomatous basal cell skin cancer. Subjects with a history of malignancy who have been cancer free for 5 years or more may be enrolled.
• Subjects who are currently using disallowed medications or will be unable to complete the medication washout periods. Subjects taking a prohibited concurrent medication which requires a washout of >30 days may be rescreened when the washout of the prohibited concurrent medication has been met.
• Subjects with life threatening/unstable respiratory status, including upper or lower respiratory tract infection, within the previous 30 days prior to screening.
• Subjects who have had a change in dose or type of any medications for COPD within 2 weeks prior to the screening visit. Subjects not on a stable dose of COPD medications may be rescreened after being on a stable dose for at least 14 days
• Subjects with a chest x ray taken ≤3 months prior to screening that suggests a diagnosis other than COPD (eg, diagnostic of pneumonia, other infection, atelectasis, or pneumothorax or other active/ongoing pulmonary conditions). If there is no chest x ray taken ≤3 months prior to screening, or if recent results are unavailable for review, a chest x ray must be performed prior to visit 2. Subjects with a medical condition that caused the abnormal finding, but, in the opinion of the Principal Investigator or designee the medical condition could resolve, may be rescreened when the condition is resolved
• Subjects with a positive urine drug test during screening.
• Subjects with a known history of alcohol abuse may be enrolled in the study if the subject's current alcohol use does not exceed more than 3 alcoholic beverages per day.
• Subjects whose schedule or travel prevents the completion of all required visits.
• Subjects who are scheduled for inpatient hospitalization or elective surgery (inpatient or outpatient) during the trial. Subjects may be rescreened when the condition is resolved.
• Subjects have participated in an investigational drug study and/or any COPD interventional trial within 30 days prior to screening or who are currently participating in another investigational drug study or COPD interventional trial.
• Subjects with a history of allergic reaction to the study medication or any components of the study medications.
• Subjects who are study site staff members or relatives of study site staff members directly involved in this study.
• Subjects with clinically significant cardiac, (Functional Class III and IV; Objective Class C and D by New York Heart Association [NYHA] Functional Classification),hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arformoterol 15 mcg twice daily; Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.	Drug: Arformoterol; Arformoterol Tartrate Inhalation Solution 15 mcg twice daily (BID) for a duration of one year; Other Names: Brovana
Placebo Comparator: Placebo twice daily; Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.	Drug: Placebo; Placebo inhalation solution, twice daily (BID) for a duration of one year.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time From Randomization to Respiratory Death or First COPD Exacerbation Related Hospitalization (Whichever Occurs First).	COPD exacerbation: an increase in COPD symptoms that necessitated any change in baseline medication (bronchodilators,anti-inflammatory agents, antibiotics, supplemental oxygen therapy, etc.).Hospitalization: any inpatient admission or any emergency department visit > 24 hours in duration. Hospice was considered hospitalization.COPD exacerbation related hospitalization: hospitalization that was due to 1) COPD exacerbation or 2) a COPD exacerbation preceded, or occurred concomitantly with the onset of, the event for which the subject was hospitalized.Respiratory-related death: For each death the Primary Investigator designated a 'probable cause', which was the primary condition that precipitated the terminal events that were the immediate cause of death. If a probable cause could not be ascertained, the cause of death was considered 'UNKNOWN'. Cause other than 'UNKNOWN' was categorized as either respiratory or non-respiratory. Deaths of 'UNKNOWN' cause were counted as primary events.	0-12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Incidence of Protocol Defined COPD Exacerbations.	A protocol-defined exacerbation of COPD was defined as an increase in respiratory symptoms (classically, increased shortness of breath, increased sputum production, and/or increased sputum purulence) that necessitates any change in baseline medication other than bronchodilators (e.g., anti-inflammatory agents, antibiotics, supplemental oxygen therapy, etc) or causes the subject to require additional medical attention (i.e., emergency room visit or hospitalization).	0-12 months
The Incidence of All Cause Mortality	Survival status at the end of the study will be determined for each subject. The proportion of subjects dead and the annual event rate will be summarized by treatment.	0-12 months
The Incidence of Treatment Emergent AEs	TEAEs were defined as: 1) adverse events that occurred on or after the date of first dose of study medication, 2) adverse events with a missing start date and a stop date on or after the date of first does of study medication, or 3) adverse events with both a missing start and stop date. The frequency and percentage of subjects with TEAEs were summarized. At each level of summarization, a subject was counted only once for each AE he/she experienced within that level. The percentage of subjects having had at least 1 AE at each level was calculated.	0-12 months
SGRQ: Mean Change From Baseline in Total Score	The SGRQ assessed health status and consisted of 3 component scores (Symptoms, Activity, and Impacts) as well as a total score. Items were scored in accordance with the developer's guidelines. Scores were expressed as a percentage of overall impairment, where 100 represented worst possible health status and 0 indicated best possible health status. The SGRQ was assessed pre-dose at baseline, months 3, 6 and 12 or the end of study (EOS). Visit 2 was defined as baseline. A change from baseline in the Total Score of ≥ 4 units is considered the minimal clinically important difference (MCID) for SGRQ.	Baseline and on treatment at months 3, 6 and 12 (or early termination)
FEV1: Mean Change From Baseline	FEV1 was measured at Visit 1 (screening), pre- and post-albuterol administration for reversibility testing, pre-dose at baseline, months 3, 6, 9 and 12/EOS. The best FEV1 from at least 3 acceptable maneuvers was recorded. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last FEV1 value obtained prior to first treatment was used for baseline.	Baseline and on treatments at months 3, 6, 9 and 12 (or early termination)
Percent Predicted FEV1: Mean Change From Baseline	Percent predicted FEV1: measured FEV1 as a percent of the "predicted values" for the patients of similar characteristics (height, age, sex, and sometimes race and weight). Best FEV1 percent predicted was measured at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS, as described for FEV1.	Baseline and on treatments at months 3, 6, 9 and 12 (or early termination)
Forced Vital Capacity (FVC): Mean Change From Baseline	Forced Vital capacity: the volume of air that can forcibly be blown out after full inspiration. Best FVC was measured at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS. The best FVC from at least 3 acceptable maneuvers was recorded.	Baseline and on treatment at months 3, 6, 9 and 12 (or early termination)
Inspiratory Capacity (IC): Mean Change From Baseline	IC: the total amount of air that can be drawn into the lungs after normal expiration. IC was measured pre- and post-albuterol administration at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS. IC maneuvers were done in triplicate. The mean of all recorded IC values was used for each subject at each time point. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last IC value obtained prior to first treatment dose was used for baseline.	Baseline and on treatment at months 3, 6, 9 and 12 (or early termination)

Collaborators and Investigators

• Sponsor: Sunovion

Publications and helpful links

General Publications

• Donohue JF, Ganapathy V, Bollu V, Stensland MD, Nelson LM. Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year. Clin Ther. 2017 Jan;39(1):66-74. doi: 10.1016/j.clinthera.2016.11.021. Epub 2016 Dec 20.
• Donohue JF, Hanania NA, Make B, Miles MC, Mahler DA, Curry L, Tosiello R, Wheeler A, Tashkin DP. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014 Dec;146(6):1531-1542. doi: 10.1378/chest.14-0117.

Study record dates

Study Major Dates

• Study Start: June 1, 2009
• Primary Completion (Actual): June 1, 2012
• Study Completion (Actual): June 1, 2012

Study Registration Dates

• First Submitted: May 26, 2009
• First Submitted That Met QC Criteria: May 27, 2009
• First Posted (Estimate): May 28, 2009

Study Record Updates

• Last Update Posted (Estimate): November 11, 2013
• Last Update Submitted That Met QC Criteria: September 12, 2013
• Last Verified: September 1, 2013

More Information

Terms related to this study

• Keywords: Chronic obstructive pulmonary disease (COPD); respiratory; long-acting beta agonist (LABA)
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Adrenergic Agonists; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Formoterol Fumarate
• Other Study ID Numbers: 091-080

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No